View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 30, 2022

Fusion doses first subject in Phase I/II solid tumour therapy trial

FPI-1966 acts on and offers an alpha-emitting medical isotope, actinium-225, to cancer cells that express FGFR3.

Fusion Pharmaceuticals has dosed the first subject in the Phase I/II clinical trial of [225Ac]-FPI-1966 (FPI-1966) in advanced solid tumours expressing fibroblast growth factor receptor three (FGFR3) patients. 

The multicentre, open-label trial will analyse the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics of FPI-1966 in FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumour patients. 

It has a three + three dose escalation design to assess various ascending doses of FPI-1966. 

To determine the effect of pre-dosing on tumour uptake and pharmacokinetics, the first cohort will have sub-groups in which several dosages of non-radiolabeled vofatamab (cold antibody) will be assessed. 

Subjects will receive FPI-1967, an imaging analogue of FPI-1966, and people whose imaging meet the predefined tumour uptake will be given FPI-1966. 

The Phase II segment will have two tumour-specific cohorts and one basket cohort.

After initial experience with subject screening through FPI-1967 imaging for predicting the pace of participant enrolment, the company intends to offer guidance on timing for the initial pharmacokinetic, imaging and safety data.

FPI-1966 is a targeted alpha therapy and can act on and offer an alpha-emitting medical isotope, actinium-225, to cancer cells that express FGFR3.

Leveraging the Fast-Clear linker of the company, FPI-1966 connects to a human monoclonal antibody targeting FGFR3, vofatamab, with actinium-225.

Fusion Pharmaceuticals CEO John Valliant said: “This study will evaluate FPI-1966 in patients with solid tumours expressing FGFR3, a validated cancer target found in multiple tumour types with substantial unmet need, notably bladder, ovarian, and head and neck cancers. 

“FPI-1966, and the growing number of TATs in our pipeline, are designed as next-generation antibody-drug conjugates [ADCs] in that they leverage the potency of actinium-225 and alpha particle radiation in place of chemical toxins to selectively eradicate cancer cells.”

The company nominated the first targeted alpha therapy (TAT) candidate under a partnership agreement with AstraZeneca to begin Phase I trials.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena